Company: PCRX
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001396814-25-000041
Chunk: 18

Company: Pacira BioSciences, Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 16
Chunk 18
---
(106,796)247 870,130 Vested restricted stock units501 — 1 — — — — 1 Common stock withheld for employee withholding tax liabilities on vested restricted stock units(19)— — — (491)— — (491)Common stock issued under employee stock purchase plan115 — — — 2,298 — — 2,298 Stock-based compensation— — — — 51,171 — — 51,171 Purchase of treasury stock, inclusive of excise tax— (837)— (25,121)— — — (25,121)Purchase of capped call transaction, net of tax— — — — (20,176)— — (20,176)Other comprehensive income (Note 12)— — — — — — 96 96 Net loss— — — — — (99,560)— (99,560)Balance at December 31, 202447,078 (837)$47 $(25,121)$1,009,435 $(206,356)$343 $778,348 

See accompanying notes to consolidated financial statements.

Pacira BioSciences, Inc.  |  2024 Annual Report on Form 10-K  |  Page F-8

PACIRA BIOSCIENCES, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands) Year Ended December 31, 202420232022Operating activities:   Net (loss) income$(99,560)$41,955 $15,909 Adjustments to reconcile net (loss) income to net cash provided by operating activities:   Goodwill impairment163,243 — — Loss on lease terminations2,165 — — Deferred taxes20,621 15,615 (7,945)Depreciation of fixed assets and amortization of intangible assets78,785 75,574 91,501 Amortization of debt issuance costs3,130 2,996 4,400 Amortization of debt discount92 752 2,807 (Gain) loss on early extinguishment of debt(7,518)16,926 — Stock-based compensation51,171 47,895 48,